Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology... Read More

CORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today announced that on September 15, 2025 it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with... Read More

CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today issued a Letter to Shareholders from Sergio Traversa, Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a truly transformational year for Relmada... Read More

6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start Phase III registration trial in 1H 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in 1H 2026 Conference Call... Read More

CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and... Read More

Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous... Read More

Appointment highlights DIMERx’s next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL Initiative SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent Director to its Board of Directors, effective... Read More

Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications,... Read More

Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi... Read More

CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.... Read More

90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation* NDV-01 showed promising clinical activity in BCG-naïve and BCG-unresponsive patients, with favorable overall tolerability Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- Relmada... Read More

CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29 th in Las Vegas. Abstract Overview Abstract Title: Prospective Open Label Study to Evaluate the Safety and Efficacy of intravesical... Read More

April 28 th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced it will host a virtual key opinion leader (KOL) event on Monday,... Read More

CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29 th in Las Vegas. Abstract Overview Abstract Title: Prospective Open Label Study to Evaluate the Safety and Efficacy of intravesical... Read More

CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29 th in Las Vegas. Abstract Overview Abstract Title: Prospective Open Label Study to Evaluate the Safety and Efficacy of Safety and Efficacy... Read More

Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today... Read More

CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31,... Read More

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually) Topline efficacy and safety Phase 2 data expected to be reported at the American Urological Association meeting (AUA), being held April 26-29, 2025 in Las Vegas NDV-01 has... Read More

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement in Tourette symptoms, quality of life and robust overall safety, supporting Sepranolone as a new potential first line treatment option for TS Sepranolone (isoallopregnanolone) is a first-in-class compound from new subgroup of... Read More

CORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that in light of the recent data monitoring committee (DMC) evaluation of the full dataset from the Reliance II Phase 3 study of the Company's REL-1017 program, the Company will discontinue the... Read More

The DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the development of REL-P11 for metabolic disease Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024 CORAL GABLES, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the... Read More

CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Jefferies London Healthcare Conference details :... Read More

REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight subjects With positive results, Phase 2a proof-of-concept study expected to begin in H1 2025 CORAL GABLES, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology... Read More

Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Nov. 07, 2024 (GLOBE... Read More

CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024. Conference Call... Read More

Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on track to initiate Phase 1 study for REL-P11 for metabolic disorders by YE 2024 Cash position of $70.4 million provides runway through key milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla. , Aug. 7, 2024... Read More

CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024. Conference Call and... Read More

CORAL GABLES, Fla. , June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry . The article is titled, " Efficacy and Safety of Esmethadone (REL-1017) in Patients with... Read More

CORAL GABLES, Fla. , June 10, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa , Chief Executive Officer, will participate in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference in Miami, Florida on Wednesday, June 12, 2024 , at 11:20am ET . Management will also... Read More

CORAL GABLES, Fla. , June 3, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa , Chief Executive Officer, and Maged Shenouda , Chief Financial Officer, will participate in a fireside chat on Thursday, June 6, 2024 , at 7:30am ET at the 2024 Jefferies Global Healthcare Conference in... Read More

CORAL GABLES, Fla. , May 8, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2024 . The Company will host a conference call today, Wednesday, May 8, at 4:30 PM Eastern Time/ 1:30 PM Pacific... Read More

CORAL GABLES, Fla. , May 6, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2024 after the market close on Wednesday, May 8, 2024 . The company will host a corporate update conference call and live audio webcast at 4:30 p.m.... Read More

CORAL GABLES, Fla. , March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2023 . The Company will host a conference call today, Tuesday, March 19, at 4:30 PM Eastern... Read More

CORAL GABLES, Fla. , March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2023 after the market close on Tuesday, March 19, 2024 . The company will host a corporate update conference call and live... Read More

CORAL GABLES, Fla. , March 5, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa , Chief Executive Officer, and Maged Shenouda , Chief Financial Officer will participate in the Leerink Partners Global Biopharma Conference in one-on-one investor meetings, taking place March 11-13, 2024... Read More

Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated Relmada's Strong Balance Sheet to Support the Company Through All of 2024's Expected Critical Catalysts CORAL GABLES, Fla. , Jan. 4, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update,... Read More

CORAL GABLES, Fla. , Nov. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2023 . The Company will host a conference call today, Wednesday, November 8, at 4:30 PM Eastern Time/ 1:30 PM... Read More

CORAL GABLES, Fla. , Nov. 3, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2023 after the market close on Wednesday, November 8, 2023 . The company will host a corporate update conference call and live audio webcast at... Read More

Low-dose psilocybin generated statistically significant reductions in liver fat content, plasma glucose levels and body weight gain in a mice model with high-fat-high-fructose diet (HFHFD)-induced metabolic dysfunction-associated steatotic liver disease (MASLD) without detrimental CNS effects Mechanism of action of psilocybin distinct from that of GLP-1 drugs and could be complementary Company intends to initiate the... Read More

CORAL GABLES, Fla. , Oct. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa , Chief Executive Officer, Maged Shenouda , Chief Financial Officer, and Cedric O'Gorman , Chief Medical Officer, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit in one-on-one investor... Read More

CORAL GABLES, Fla. , Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36 th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023 , in Barcelona, Spain . Details of the poster presentations are as follows:... Read More

Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment Long-term dosing with REL-1017 was well-tolerated, with low rates of adverse events and discontinuations due to adverse events, and no new... Read More

CORAL GABLES, Fla. , Aug. 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the dosing of the first patient in the Relight (study 304) Phase 3, randomized, double-blind, placebo-controlled trial evaluating REL-1017 as an adjunctive treatment of Major Depressive Disorder (MDD). "The dosing of the first... Read More

CORAL GABLES, Fla. , Aug. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the second quarter ended June 30, 2023 . The Company will host a conference call today, Tuesday, August 8, at 4:30 PM Eastern Time/ 1:30 PM Pacific... Read More

CORAL GABLES, Fla. , Aug. 1, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 8, 2023 . The company will host a corporate update conference call and live audio webcast at 4:30... Read More

CORAL GABLES, Fla. , June 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa , Chief Executive Officer, Maged Shenouda , Chief Financial Officer, and Cedric O'Gorman , Chief Medical Officer, will participate in the Goldman Sachs Global Healthcare Conference in one-on-one investor... Read More

CORAL GABLES, Fla. , June 2, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa , Chief Executive Officer, Maged Shenouda , Chief Financial Officer, and Cedric O'Gorman , Chief Medical Officer, will participate in the 2023 Jefferies Global Healthcare Conference in one-on-one investor... Read More

CORAL GABLES, Fla. , May 24, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in-person in two late-breaking poster presentations at the American Society of Clinical Psychopharmacology 2023 Annual Meeting. The... Read More

CORAL GABLES, Fla. , May 11, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023 . The Company will host a conference call today, Thursday, May 11, at 4:30 PM Eastern Time/ 1:30 PM Pacific... Read More

CORAL GABLES, Fla. , May 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 11 th , 2023. The company will host a corporate update conference call and live audio webcast at 4:30... Read More

CORAL GABLES, Fla. , March 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full-year ended December 31, 2022 . The Company will host a conference call today, Thursday, March 23, at 4:30 PM Eastern... Read More

CORAL GABLES, Fla. , March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2022 after the market close on Thursday, March 23, 2023 . The company will host a corporate update conference call and live... Read More

CORAL GABLES, Fla. , Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli , Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent... Read More

CORAL GABLES, Fla. , Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer. Dr. O'Gorman will lead medical, clinical and regulatory functions in support of the Company's late-stage REL-1017 development program. Dr. O'Gorman... Read More

Company to Host Conference Call Today, December 7, 2022 , at 5:00 PM ET CORAL GABLES, Fla. , Dec. 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced results of the RELIANCE I study (REL-1017-301), evaluating REL-1017 as an adjunctive treatment for Major Depressive Disorder (MDD). The same factors that... Read More